Does IRADIMED’s (IRMD) Upbeat Guidance Reveal New Drivers for Sustained Margin Expansion?

Simply Wall St.

Nov 11

IRADIMED CORPORATION recently reported third quarter and nine-month 2025 results, revealing year-over-year growth in revenue and net income, and raised its full-year 2025 revenue and earnings guidance...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582330022"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582330022\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582330022?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2025-11-11 14:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582330022","market":"hk","top_or_hot":-1,"title":"Does IRADIMED’s (IRMD) Upbeat Guidance Reveal New Drivers for Sustained Margin Expansion?","media":"Simply Wall St.","content":"<div>\n<p>IRADIMED CORPORATION recently reported third quarter and nine-month 2025 results, revealing year-over-year growth in revenue and net income, and raised its full-year 2025 revenue and earnings guidance...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-irmd/iradimed/news/does-iradimeds-irmd-upbeat-guidance-reveal-new-drivers-for-s\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does IRADIMED’s (IRMD) Upbeat Guidance Reveal New Drivers for Sustained Margin Expansion?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes IRADIMED’s (IRMD) Upbeat Guidance Reveal New Drivers for Sustained Margin Expansion?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-11 14:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-irmd/iradimed/news/does-iradimeds-irmd-upbeat-guidance-reveal-new-drivers-for-s><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IRADIMED CORPORATION recently reported third quarter and nine-month 2025 results, revealing year-over-year growth in revenue and net income, and raised its full-year 2025 revenue and earnings guidance...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-irmd/iradimed/news/does-iradimeds-irmd-upbeat-guidance-reveal-new-drivers-for-s\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-irmd/iradimed/news/does-iradimeds-irmd-upbeat-guidance-reveal-new-drivers-for-s","article_id":"2582330022","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-irmd/iradimed/news/does-iradimeds-irmd-upbeat-guidance-reveal-new-drivers-for-s","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2582330022","pubTimestamp":1762841779,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"IRADIMED CORPORATION recently reported third quarter and nine-month 2025 results, revealing year-over-year growth in revenue and net income, and raised its full-year 2025 revenue and earnings guidance.\nThe company’s ability to lift full-year projections after another period of double-digit sales growth highlights management’s confidence in ongoing demand for its MRI-compatible medical devices.\nWe’ll explore how IRADIMED’s raised guidance could influence its long-term growth narrative and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","IRMD":"iRadimed Corporation"},"translate_title":"IRADIMED(IRMD)的乐观指引是否揭示了利润率持续扩张的新驱动力？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRMD":1.5},"content_text":"IRADIMED CORPORATION recently reported third quarter and nine-month 2025 results, revealing year-over-year growth in revenue and net income, and raised its full-year 2025 revenue and earnings guidance. The company’s ability to lift full-year projections after another period of double-digit sales growth highlights management’s confidence in ongoing demand for its MRI-compatible medical devices. We’ll explore how IRADIMED’s raised guidance could influence its long-term growth narrative and outlook for margin expansion. We've found 16 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.AdvertisementIRADIMED Investment Narrative RecapStaying invested in IRADIMED requires confidence in continued demand for its MRI-compatible devices and belief in the management’s ability to convert innovation into market growth, particularly as hospital capital spending remains a key catalyst. The latest raised guidance, off the back of double-digit sales and income growth, clearly reinforces near-term optimism, though margin pressure from tariff-related input costs, a persistent concern, hasn’t materially changed due to this update. Among recent announcements, the company’s revised full-year 2025 revenue and earnings guidance stands out as most relevant, setting a higher baseline for expectations and highlighting ongoing momentum from key product lines. This update helps keep the spotlight firmly on short-term execution, even as supply chain and competitive risks remain present in the background. But while higher near-term earnings are promising, investors should not lose sight of the potential consequences if global input cost pressures start to intensify... Read the full narrative on IRADIMED (it's free!)IRADIMED's outlook forecasts $104.0 million in revenue and $28.3 million in earnings by 2028. This assumes a 10.2% annual revenue growth rate and a $7.6 million increase in earnings from the current $20.7 million.Uncover how IRADIMED's forecasts yield a $82.50 fair value, a 4% downside to its current price.Exploring Other PerspectivesIRMD Community Fair Values as at Nov 2025 Four Simply Wall St Community members place IRADIMED’s fair value anywhere between US$27.86 and US$82.50 per share. Opinions vary, especially as global cost risks linger and could weigh on future profitability, so consider several viewpoints before deciding.Explore 4 other fair value estimates on IRADIMED - why the stock might be worth less than half the current price!Build Your Own IRADIMED NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your IRADIMED research is our analysis highlighting 2 key rewards that could impact your investment decision.Our free IRADIMED research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IRADIMED's overall financial health at a glance.Contemplating Other Strategies?Opportunities like this don't last. These are today's most promising picks. Check them out now:This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.Uncover the next big thing with financially sound penny stocks that balance risk and reward.AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}